The TOP list of the world's most high -efficiency pharmaceutical companies is released!There are only 3 century -old pharmaceutical companies

The TOP list of the world's most high -efficiency pharmaceutical companies is released! There are only 3 hundred -year pharmaceutical companies, Albervi, Pfizer, Lili Lili ...

Source: Yaozhi.com/Forest

How does a pharmaceutical company maintain efficient operation?

Large -scale pharmaceutical companies are usually strong in capital and strong talent teams. They can increase the overall winning rate by means of mergers and acquisitions and adjustment of product pipelines. And biotechnology companies usually have advantages in a certain frontier field. What we must do is focus on their own tracks and technology, and then wait for the wind.

A few days ago, the industry media Fiere Pharma released TOP10, the world's most high -efficiency bioplasm company in 2021, confirming this.

In general, 9 of the 10 companies on the list have revenue more than $ 1 million per capita, while only 4 years ago. Of the 10 companies, 7 companies benefited from the new vaccine or new crown drugs, and significantly increased their per capita income.

Note: The list only counts pharmaceutical companies with a revenue of more than 10 billion US dollars in 2021; revenue per capita revenue is 2021, with the total number of employees of the company

Data source: Reference Data

With MRNA new crown vaccine

Biontech/ Moderna on the top

Three years ago, the new crown epidemic broke out, and the success of the MRNA new crown vaccine made Biontech and Moderna top the top of the world's highest -effect pharmaceutical companies. The two companies have about 3,000 employees, which have created about $ 20 billion in revenue, a per capita income of nearly 7 million US dollars, much higher than the third -ranked Geely German science company.

But in the R & D model, BionTech and Moderna adopt different ways.

Biontech chose to cooperate with Pfizer and Fosun Pharmaceuticals in China to quickly push its new crown vaccine to the market. But this did not weaken the strength and income of the German biotechnology company.

As of the end of 2021, Biontech had 3,082 employees worldwide, an increase of about 1,000 from the number of employees in 2020. In 2021, the company's per capita revenue was $ 7.28 million, becoming the world's most efficient biopharmaceutical company.

This year, BionTech is still increasing employees, expanding manufacturing and developing MRNA production projects. It is already one of the world's largest MRNA vaccine factories in the Malburg factory in Germany, but Biontech said it will also invest about 50 million euros (about 56.4 million US dollars). In addition, the cooperation between BIONTECH and reg year and other companies in the field of cancer has turned their attention to other projects such as MRNA projects and cell therapy in the future.

Unlike BIONTECH, Moderna did not cooperate, but plans to build a MRNA empire.

In order to achieve this goal, the number of employees of Moderna increased rapidly from 820 in 2019 to 2,700 in 2021. With its MRNA new crown vaccine Spikevax, Moderna achieved revenue of US $ 18.47 billion in 2021, with a per capita revenue of US $ 6.84 million, which was slightly lower than Biontech.

In February this year, Moderna said it would open a plan to open four new subsidiaries in Hong Kong, Malaysia, Singapore and Taiwan to expand the sales area. Moderna also plans to carry out commercial projects in European regions such as Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden. In the next step, Moderna will continue to develop MRNA therapy for anti -influenza and cancer.

Gillar has 1,4400 employees, which achieved $ 27 billion in revenue in 2021, with a per capita revenue of about 1.95 million US dollars. Of course, Geely also received $ 5.6 billion in sales from the new crown drug Veklury.

The fourth regeneration yuan, before 2021, already has one of the most efficient employee teams in the field of biopharmaceuticals. In the past, the company had developed heavy drugs such as Eylea, which treats macular degeneration and Dupixent, which treats eczema and asthma.

When the new crown broke out, the regenerative yuan responded quickly and launched the COVID-19 antibody cocktail therapy "Regen-COV" for the treatment of high-risk groups. The therapy revenue in 2021 was US $ 7.574 billion, helping the regenerative yuan on the list.

M & A and Alliance

Big pharmaceutical companies borrowed their efforts to break through

By cooperating with Biontech, Pfizer obtained its mRNA vaccine (commodity: Comingaty) in the United States and Europe and other regions. In 2021, it realized a sales of nearly $ 37 billion through the vaccine. It also enabled Pfizer to per capita in 2021 The income was almost overwhelming compared to 2020. On the other hand, Pfizer stripped UPJOHN in the fourth quarter of 2020, controlled the number of employees, and revenue per capita revenue to $ 1.03 million.

The Olumiant, which cooperates with Eric and Incete for new crown patients, and the sales of new crowns and antibody drugs in cooperation with companies such as Junshi Biology reached 2.24 billion U.S. dollars, accounting for about 8%of the total sales. In fact, Li Lili has been cutting costs for many years and increasing new drug research and development to improve the company's efficiency. In early 2017, shortly after CEO David Ricks at the helm, the company launched a large -scale cost reduction action to save $ 1.2 billion per year. At the same time, the income of Lilly Company has increased during this period, significantly increased the productivity of each employee. Since the beginning of this year, Lilly has brought out the progress of multiple pipelines in the vibration industry, including Tirzepatide obtained FDA approval, EMPAGLIFLOZIN new heart failure indications, CKD phase 3 clinical clinical ending, Baricitinib new alopecia are globe indication, and Mirikizumab submits BLA, etc. In addition, in 2016, Celgene and Allergan have been acquired by the Bellet Semitami (BMS) and Albervi, respectively. These two companies have been nearly two companies in the past two. The TOP list of the world's most high -efficiency pharmaceutical companies occupies a place.

In 2019, BMS acquired the second place ranked second in the year with $ 74 billion. After the merger, BMS saves costs through integration, layoffs, etc., and due to the increase in sales of best -selling drugs such as Revlimid, Eliquis, and OPDIVO, BMS ranks fifth in this year's list, and it is the highest -known pharmaceutical company with more than 100 years of history. One family.

Also in 2019, Albervi acquired Ailjian and brought $ 4.68 billion in revenue last year, an increase of 87%over 2020. However, Humira is still the company's most important source of revenue. The drug in 2021 was as high as US $ 20.7 billion in 2021, accounting for 37%of Albervi's total sales. As HUMIRA will face tremendous pressure on generic drugs in 2023, how to keep the future financial situation of Albervis remains to be observed. However, its new immunology products Skyrizi and RinvoQ's revenue growth is considerable. Abervine predicts that by 2025, the total sales of these two immunotherapies will reach $ 15 billion.

Compared with the rapid progress of other biopharmaceutical companies, Anjin has been shocked in recent years. Like BMS and Albervi, Anjin has not been able to successfully launch new crown products in the past few years, but Anjin's global sales in 2021 reached $ 25.98 billion, and per capita revenue reached 1.07 million US dollars, exceeding most companies in the industry. In addition, Lumakras, a new lung cancer approved by Anjin by Anjin last year, has attracted much attention. After breaking the curse of KRAS's incompetent medicine, this year's WCLC has announced a number of joint medication data, which is expected to become heavy bombs.

Of course, the development of new drugs is not always so lucky. In 2021, Bo Jian's failure of ADuhelm, the drug of Azheimer's Disease, and multiple factors such as the seizing market of multiple sclerosis, and the per capita revenue was below 2020 in 2021. It is the only company in the list with revenue and reduction in revenue.

Reference source:

https://www.fiepharma.com/special- reports/top-10-most-productive-biopharma- companies

- END -